The n2 paradox: Similar outcomes of pre- and postoperatively identified single-zone n2a positive non-small-cell lung cancer†

European Journal of Cardio-thoracic Surgery

Volumn 45, Issue 5, 2014, Pages 882-887

  Tsitsias, Thomas ^a   Boulemden, Anas ^a   Ang, Keng ^a   Nakas, Apostolos ^a   Waller, David A ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Lung cancer; Lymph nodes; Mediastinum; Single zone; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINOSCOPY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; THORAX RADIOGRAPHY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84898631463     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezt478     Document Type: Article

References (20)

1. Detterbeck F. What to do with 'surprise' N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 2008;3: 289-302.
2. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P; Members of IASLC Staging Committee. The IASLC lung cancer staging project: A proposal for a new interventional lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:568-77.
3. Lardinois D, De Leyn P, Van Schil PE, Porta RR, Waller DA, Passlick B et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787-92.
4. Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M et al. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2007;2:603-12.
5. Vansteenkiste JF, De Leyn PR, Deneffe GJ, Lerut TE, Demedts MG. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer 1998;19:3-13.
6. Martini N, Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-49.
7. Pearson F, De Larue N, Ilves R, Todd TR, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83: 1-11.
8. Andre F, Grunewald G, Pignon JP, Dujon A, Pujol JL, Brichon PY et al. Survival of patient with resected N2 non-small cell lung cancer: evidence for a subclassification and implication. J Clin Oncol 2000;18: 2981-9.
9. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1017-23.
10. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF et al. Results of the American college of surgeons' oncology group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small lung cancer. J Thorac Cardiovasc Surg 2003;126: 1943-51.
11. Van Tinteren H, Hoekstra OS, Smit EF, Van de Bergh JH, Schreurs AJ, Mourik JC et al. Effectiveness of PET in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS multicenter randomized trial. Lancet 2002;359:1388-92.
12. Meyers BF, Haddad F, Siegel BA, Zoole JB, Battafarano RJ, Veeramachaneni N et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 2006;131: 822-9.
13. Landreanu RJ, Hazelrigg SR, Mack MJ, Fizgibbon LD, Dowling RD, Acuff TE et al. Thoracoscopic mediastinal lymph node sampling: a useful approach to mediastinal lymph node stations inaccessible to cervical medistinoscopy. J Thorac Cardiovasc Surg 1993;106:554-8.
14. Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg 2011; 142:1393-400.
15. Cerfolio RJ, Bryant AS, Eloubeidi MA, Frederick PA, Minnich DJ, Harbour KC et al. The true false negative rates of esophageal and endobronchial ultrasound in the staging of mediastinal lymph nodes in patients with non-small cell lung cancer. Ann Thorac Surg 2010;90: 427-34.
16. Waller D, Skwarski KM. Is there still a role for mediastinoscopy as the first mediastinal staging procedure in lung cancer? J R Coll Physicians Edinb 2013;43:137-43.
17. Izbicki JR, Passlick B, Karg O, Bloechle C, Pantel K, Knoefel WT et al. Impact of radical systematic lymphadenectomy on tumour staging in lung cancer. Ann Thorac Surg 1995;59:209-14.
18. Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with stage II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 2000; 70:358-66.
19. Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg 2012;93: 1807-12.
20. Albain KS, Swan RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.